Eco Animal Health Group PLC Deferred Share Option Awards (5871J)

TIDMEAH

RNS Number : 5871J

Eco Animal Health Group PLC

13 December 2022

13 December 2022

ECO Animal Health Group plc

("ECO" or the "Company")

Deferred Share Option Awards to Executive Director & PDMRs

ECO Animal Health Group plc announces that on 12 December 2022, deferred nominal cost share options were granted under the Company's Deferred Bonus Plan ("DBS") over 45,606 ordinary shares in the Company (representing approximately 0.07 percent of the Company's issued share capital) to an Executive Director and members of the Company's Executive Leadership Team ("ELT") listed below. These awards relate to the deferral of 33% and 20% of the annual bonus for Executive Directors and members of ELT respectively earned in respect of the Company's financial year ended 31 March 2022.

 
 Name                                 Position                 Number of Deferred 
                                                                  Share Options 
 Chris Wilks             Chief Financial Officer                     4,309 
                        ------------------------------------  ------------------- 
                         Head of Global Research and 
 Hafid Benchaoui          Development                                3,666 
                        ------------------------------------  ------------------- 
                         Business Unit Head - China 
 Andrew Buglass           & Japan                                    6,872 
                        ------------------------------------  ------------------- 
 Seamus Long             Global Director of Operations               2,260 
                        ------------------------------------  ------------------- 
 Jordi Mora              Global Technical Services Director          4,507 
                        ------------------------------------  ------------------- 
 Piotr Postepski         Global Director of Sales                    14,926 
                        ------------------------------------  ------------------- 
 Oscar Romero-Galindo    Head of Global Marketing                    9,066 
                        ------------------------------------  ------------------- 
 

As indicated in the Circular to shareholders dated 4 February 2021, the DBS has been established to allow the Remuneration Committee to require a significant part of the annual bonuses paid to Executive Directors and senior management to be deferred in exchange for an award of nominal cost options which vest after 3 years.

For further information please contact:

 
 
     ECO Animal Health Group plc 
     David Hallas (CEO)                           020 8447 
     Christopher Wilks (CFO)                      8899 
    IFC Advisory 
     Graham Herring                              020 3934 
     Zach Cohen                                   6630 
    Singer Capital Markets (Nominated Adviser 
     & Joint Broker) 
     Phil Davies                                 020 7496 
     George Tzimas                                3000 
    Investec (Joint Broker) 
     Gary Clarence 
     Daniel Adams                                020 7597 
     Carlo Spingardi                              5970 
    Equity Developments 
     Hannah Crowe                                020 7065 
     Matt Evans                                   2692 
 
 
 
   About ECO Animal Health 
   ECO Animal Health Group plc researches, develops and 
   commercialises products for livestock. Our business 
   strategy is to generate shareholder value by achieving 
   the maximum sales potential from the existing product 
   portfolio whilst investing in Research and Development 
   ("R&D") for new products, particularly vaccines, and 
   seeking to in-license new products. 
 
 

PDMR Notification - ECO DBS Deferred Share Option Awards

 
 1.   Details of the person discharging managerial responsibilities 
       / person closely associated 
 a.   Name                     1. Chris Wilks 
                                2. Hafid Benchaoui 
                                3. Andrew Buglass 
                                4. Seamus Long 
                                5. Jordi Mora 
                                6. Piotr Postepski 
                                7. Oscar Romero-Galindo 
     =======================  ================================================== 
 2.   Reason for the notification 
     =========================================================================== 
 a.   Position/status          1. Chief Financial Officer 
                                2. Head of Global Research and Development 
                                3. Business Unit Head - China & Japan 
                                4. Global Director of Operations 
                                5. Global Technical Services Director 
                                6. Global Director of Sales 
                                7. Head of Global Marketing 
     =======================  ================================================== 
 b.   Initial notification     Initial notification 
       /Amendment 
     =======================  ================================================== 
 3.   Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
     =========================================================================== 
 a.   Name                     Eco Animal Health Group Plc 
     =======================  ================================================== 
 b.   LEI                      2138009XN9DJ3YP70B55 
     =======================  ================================================== 
 4.   Details of the transaction(s): section to be repeated 
       for (i) each type of instrument; (ii) each type of transaction; 
       (iii) each date; and (iv) each place where transactions 
       have been conducted 
     =========================================================================== 
 a.   Description              Options over ordinary shares of 5p each. 
       of the 
       Financial instrument,    GB0032036807 
       type of instrument 
       Identification 
       code 
     =======================  ================================================== 
 b.   Nature of the            Award of nominal cost share options under 
       transaction              the Company's DBS. 
     =======================  ================================================== 
 c.   Price(s) and             Numbers 1 to 7 in the left-hand column correspond 
       volume(s)                to the relevant PDMR as detailed in boxes 
                                1a and 2a above. 
                                 Price(s)   Volume(s) 
                                 1. 5p      4,309 
                                           ---------- 
                                 2. 5p      3,666 
                                           ---------- 
                                 3. 5p      6,872 
                                           ---------- 
                                 4. 5p      2,260 
                                           ---------- 
                                 5. 5p      4,507 
                                           ---------- 
                                 6. 5p      14,926 
                                           ---------- 
                                 7. 5p      9,066 
                                           ---------- 
     =======================  ================================================== 
 d.        Aggregated 
            information 
            Aggregated                      n/a 
            volume 
            Price 
     =======================  ================================================== 
 e.   Date of the              12 December 2022 
       transaction 
     =======================  ================================================== 
 f.   Place of the             Outside a trading venue. 
       transaction 
     =======================  ================================================== 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHGPGMCPUPPGAW

(END) Dow Jones Newswires

December 13, 2022 10:50 ET (15:50 GMT)